Related Experiment Video
Updated: Nov 3, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.5K
Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC
Sean All1, Aurelie Garant1, Raquibul Hannan1
1Department of Radiation Oncology, University of Texas at Southwestern Medical Center, Dallas, TX.
Seminars in Radiation Oncology
|June 6, 2021
Summary
Stereotactic ablative radiation (SAbR) shows promise for oligometastatic renal cell carcinoma (mRCC). This aggressive local therapy may improve disease control, quality of life, and survival in select mRCC patients.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Background:
- Metastatic renal cell carcinoma (mRCC) frequently presents with limited metastatic sites (oligometastatic disease).
- Aggressive local therapy, including stereotactic ablative radiation (SAbR), is increasingly recognized for its potential benefit in select mRCC patients.
Purpose of the Study:
- To evaluate the role of SAbR in the management of oligometastatic mRCC.
- To explore the potential benefits of SAbR beyond local control, including disease management, quality of life, and survival.
Main Methods:
- Review of retrospective and limited prospective data on SAbR for CNS and extra-cranial mRCC.
- Analysis of SAbR efficacy, toxicity, and impact on systemic therapy use.
Main Results:
- SAbR demonstrates high local control with low toxicity in oligometastatic mRCC.
- Potential benefits include longitudinal disease control, improved quality of life, delayed systemic therapy, immune modulation, and enhanced survival.
- Retrospective data suggests benefit in patients with metachronous metastases and indolent disease biology.
Conclusions:
- SAbR is a promising therapeutic option for select oligometastatic mRCC patients.
- Further large prospective trials are needed to optimize SAbR integration with systemic therapies for maximal patient benefit.
